At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antivirals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 14 Jul 1998 No-Development-Reported for Respiratory syncytial virus infections in United Kingdom (Unknown route)
- 02 Nov 1994 Preclinical development for Respiratory syncytial virus infections in United Kingdom (Unknown route)